Novo Raises 2026 Outlook for Third Time as Wegovy Pill Beats Forecasts
Strong Wegovy pill sales helped Novo Nordisk beat forecasts and lift its full-year 2026 sales and profit guidance for the third time.
Strong Wegovy pill sales helped Novo Nordisk beat forecasts and lift its full-year 2026 sales and profit guidance for the third time.
RBC calls Krystal’s Q3 mixed. Vyjuvek beat expectations, but key pipeline readouts for DEB and CF now slip into 2027. Outperform, $400 PT.
AstraZeneca posted solid 9M and Q3 results, beat forecasts, and launched a $1.5bn savings plan to fund its pipeline.
Under new CEO Garijo, Sanofi says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results.
Revenue grew 36% and non-GAAP EPS rose 70% on record Dupixent and EYLEA HD sales.
TTR franchise powers Alnylam’s Q3 results. Analysts cite decelerating Amvuttra growth and minor catalyst delays; Stifel cuts to Hold.